Published in J Cereb Blood Flow Metab on February 11, 2015
Sitagliptin Cardiovascular Outcomes Study (MK-0431-082) (TECOS) | NCT00790205
Macrophage-mediated cholesterol handling in atherosclerosis. J Cell Mol Med (2015) 0.86
Glucose-Dependent Insulinotropic Polypeptide Ameliorates Mild Traumatic Brain Injury-Induced Cognitive and Sensorimotor Deficits and Neuroinflammation in Rats. J Neurotrauma (2016) 0.80
Type 2 diabetes-induced neuronal pathology in the piriform cortex of the rat is reversed by the GLP-1 receptor agonist exendin-4. Oncotarget (2016) 0.77
An Orally Active Allosteric GLP-1 Receptor Agonist Is Neuroprotective in Cellular and Rodent Models of Stroke. PLoS One (2016) 0.76
Diabetes negatively affects cortical and striatal GABAergic neurons: an effect that is partially counteracted by exendin-4. Biosci Rep (2016) 0.75
Neurotrophic and neuroprotective effects of oxyntomodulin in neuronal cells and a rat model of stroke. Exp Neurol (2016) 0.75
Assessed and Emerging Biomarkers in Stroke and Training-Mediated Stroke Recovery: State of the Art. Neural Plast (2017) 0.75
To Use or Not to Use Metformin in Cerebral Ischemia: A Review of the Application of Metformin in Stroke Rodents. Stroke Res Treat (2017) 0.75
The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet (2006) 15.76
Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med (2013) 11.34
Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med (2013) 8.74
GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism. Proc Natl Acad Sci U S A (2009) 2.15
Neuroprotection for ischemic stroke: two decades of success and failure. NeuroRx (2004) 1.71
Design of the liraglutide effect and action in diabetes: evaluation of cardiovascular outcome results (LEADER) trial. Am Heart J (2013) 1.62
Peptide hormone exendin-4 stimulates subventricular zone neurogenesis in the adult rodent brain and induces recovery in an animal model of Parkinson's disease. J Neurosci Res (2008) 1.58
Safety of dipeptidyl peptidase-4 inhibitors: a meta-analysis of randomized clinical trials. Curr Med Res Opin (2011) 1.48
Exendin-4, a glucagon-like peptide-1 receptor agonist, provides neuroprotection in mice transient focal cerebral ischemia. J Cereb Blood Flow Metab (2011) 1.40
Receptors for the incretin glucagon-like peptide-1 are expressed on neurons in the central nervous system. Neuroreport (2009) 1.22
Ischemia-induced changes in glucagon-like peptide-1 receptor and neuroprotective effect of its agonist, exendin-4, in experimental transient cerebral ischemia. J Neurosci Res (2011) 1.20
Glucagon-like peptide-1 receptor activation reduces ischaemic brain damage following stroke in Type 2 diabetic rats. Clin Sci (Lond) (2012) 1.19
The DPP-4 inhibitor linagliptin counteracts stroke in the normal and diabetic mouse brain: a comparison with glimepiride. Diabetes (2012) 1.13
Central effects of GLP-1: new opportunities for treatments of neurodegenerative diseases. J Endocrinol (2014) 1.07
Dipeptidyl peptidase-4 inhibitors do not increase the risk of cardiovascular events in type 2 diabetes: a cohort study. Acta Diabetol (2014) 0.94
Repeated administration of exendin-4 reduces focal cerebral ischemia-induced infarction in rats. Brain Res (2011) 0.91
Activation of spinal glucagon-like peptide-1 receptors specifically suppresses pain hypersensitivity. J Neurosci (2014) 0.91
Reducing the risk of stroke in type 2 diabetes: pathophysiological and therapeutic perspectives. J Neurol (2009) 0.91
Exendin-4 reduces ischemic brain injury in normal and aged type 2 diabetic mice and promotes microglial M2 polarization. PLoS One (2014) 0.89
Glucagon-like peptide-1 decreases intracerebral glucose content by activating hexokinase and changing glucose clearance during hyperglycemia. J Cereb Blood Flow Metab (2012) 0.88
Pleiotropic mechanisms for the glucose-lowering action of DPP-4 inhibitors. Diabetes (2014) 0.87
Neuroprotective effects of liraglutide for stroke model of rats. Int J Mol Sci (2013) 0.87
Neuroprotective and anti-apoptotic effects of liraglutide in the rat brain following focal cerebral ischemia. Neuroscience (2014) 0.85
Alogliptin, a dipeptidylpeptidase-4 inhibitor, for patients with diabetes mellitus type 2, induces tolerance to focal cerebral ischemia in non-diabetic, normal mice. Brain Res (2013) 0.85
Exenatide in acute ischemic stroke. Int J Stroke (2013) 0.79
Antidiabetic treatment, stroke severity and outcome. World J Diabetes (2014) 0.78
Dipeptidyl peptidase IV, aminopeptidase N and DPIV/APN-like proteases in cerebral ischemia. J Neuroinflammation (2012) 0.78
Related expressional change of HIF-1α to the neuroprotective activity of exendin-4 in transient global ischemia. Neuroreport (2014) 0.77
The dipeptidyl peptidase inhibitor linagliptin and the angiotensin II receptor blocker telmisartan show renal benefit by different pathways in rats with 5/6 nephrectomy. Kidney Int (2016) 1.00
The DPP-IV inhibitor linagliptin and GLP-1 induce synergistic effects on body weight loss and appetite suppression in the diet-induced obese rat. Eur J Pharmacol (2014) 0.79
Glucagon-like peptide-1 receptor signalling reduces microvascular thrombosis, nitro-oxidative stress and platelet activation in endotoxaemic mice. Br J Pharmacol (2016) 0.77
Linagliptin enhances neural stem cell proliferation after stroke in type 2 diabetic mice. Regul Pept (2014) 0.76
Glucagon-like receptor 1 agonists and DPP-4 inhibitors: Anti-diabetic drugs with anti-stroke potential. Neuropharmacology (2017) 0.75
Regulation of Glycemia in the Recovery Phase After Stroke Counteracts the Detrimental Effect of Obesity-Induced Type 2 Diabetes on Neurological Recovery. Diabetes (2020) 0.75